Quantcast
Last updated on April 17, 2014 at 17:30 EDT

Latest Organogenesis Inc. Stories

2014-02-04 04:21:50

DUBLIN, February 4, 2014 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today releases historical income statements on both a US GAAP and Non GAAP basis for 2012 and the nine months ended September 30, 2013, recast to show the impact of DERMAGRAFT operations as discontinued. On January 17, 2014 Shire announced that it had entered into a definitive agreement pursuant to which it has sold certain of its DERMAGRAFT...

2014-01-17 08:23:07

Product Acquisition Solidifies Organogenesis Position as Industry Leader CANTON, Mass., Jan. 17, 2014 /PRNewswire/ -- Organogenesis Inc., a commercial leader in the field of regenerative medicine, announced today that it has purchased the Dermagraft® assets (human fibroblast-derived dermal substitute) from Shire plc (LSE: SHP, NASDAQ: SHPG). "Organogenesis is a pioneering company in the regenerative medicine and wound healing fields, and we are now the proud owners of two products...

2014-01-09 12:27:35

LONDON, Jan. 9, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report: Bioactive Wound Care Market in the US 2012-2016 TechNavio's analysts forecast the Bioactive Wound Care market in the US to grow at a CAGR of 5.26 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increase in elderly population in the US. The Bioactive Wound Care market in the US has also been witnessing an increasing adoption of...

2013-11-06 08:29:21

Fight4MyFeet is a Program Raising Awareness and Providing Education around Diabetic Foot Ulcers CANTON, Mass., Nov. 6, 2013 /PRNewswire/ -- Organogenesis Inc., a commercial leader in the field of regenerative medicine, is launching Fight4MyFeet, an educational program and online resource focused on proper foot hygiene within the diabetic community. Fight4MyFeet offers patients and clinicians tools and strategies to help ensure the best chance of healing a diabetic foot ulcer....

2013-10-21 16:25:32

CANTON, Mass., Oct. 21, 2013 /PRNewswire/ -- The Galien Foundation, a foundation which fosters, recognizes and rewards excellence in scientific innovation to improve the state of human health, has nominated Organogenesis Inc.'s newest FDA approved product, GINTUIT((TM)) (Allogeneic Cultured Keratinocytes and Fibroblasts in Bovine Collagen) for the seventh annual Prix Galien USA Awards in the "Best Biotechnology Product" category. The Prix Galien Award, which recognizes the...

2013-09-10 12:29:17

PITTSBURGH, Sept. 10, 2013 /PRNewswire/ -- Net Health, the outpatient specialty care leader, is pleased to announce an update to the Cell and Tissue Based Products module available in the WoundExpert® software, in collaboration with industry leaders Organogenesis Inc. and Soluble Systems®. This enhancement to the Net Health Connections Program facilitates insurance verification, submission of supporting documentation, and automated ordering with order status updates completely...

2013-08-21 08:25:49

CANTON, Mass., Aug. 21, 2013 /PRNewswire/ -- Organogenesis Inc., a commercial leader in the field of regenerative medicine, is announcing Pujitha Ganni as the winner of its annual college scholarship. The award honors the achievement of a graduating Canton High School senior interested in pursuing a career in medicine, life sciences research, or biomedical engineering. Ms. Ganni, who graduated among the top in her class with a 4.33 GPA, is attending Carnegie Mellon University in the...

2013-05-22 08:29:52

Presentations at the International Society for Pharmacoeconomics and Outcomes Research Annual Meeting Highlight the Estimated $30 Billion Annual Burden Imposed by VLUs and DFUs in the US CANTON, Mass. and NEW ORLEANS, May 22, 2013 /PRNewswire/ -- Organogenesis Inc., a commercial leader in the field of regenerative medicine, presented new data generated in collaboration with a team of expert economists from Analysis Group (a leading health economics consultancy) demonstrating the...

2013-05-06 08:31:27

Data Represents the Largest Real World Comparative Effectiveness Analysis Conducted with Apligraf CANTON, Mass., May 6, 2013 /PRNewswire/ -- Organogenesis Inc., a commercial leader in the field of regenerative medicine, announced today key findings demonstrating the speed and incidence of wound closure for venous leg ulcer (VLU) patients who were treated with Apligraf®. The oral presentation of the abstract, titled "A Retrospective Analysis of a Bilayered Living Cellular...

2013-04-30 12:27:39

Six Presentations Accepted at SAWC/WHS to Highlight Scientific Characteristics of Apligraf®, Real World Effectiveness in VLU Patients and Economic Burden of DFUs and VLUs CANTON, Mass., April 30, 2013 /PRNewswire/ -- Organogenesis Inc., a commercial leader in the field of regenerative medicine, announced today that it will present new Apligraf® comparative effectiveness data and chronic wound burden of illness economic analyses at the Symposium of Advanced Wound Care (SAWC)...